Incremental cost of pre- and post-exposure prophylaxis service provision via an online pharmacy in Kenya.

IF 2.2 3区 医学 Q3 IMMUNOLOGY
Yilin Chen, Michalina A Montaño, Paulami Naik, Nicholas Thuo, Catherine Kiptinness, Maeve Rafferty, Andy Stergachis, Melissa Latigo Mugambi, Kenneth Ngure, Katrina F Ortblad, Monisha Sharma
{"title":"Incremental cost of pre- and post-exposure prophylaxis service provision via an online pharmacy in Kenya.","authors":"Yilin Chen, Michalina A Montaño, Paulami Naik, Nicholas Thuo, Catherine Kiptinness, Maeve Rafferty, Andy Stergachis, Melissa Latigo Mugambi, Kenneth Ngure, Katrina F Ortblad, Monisha Sharma","doi":"10.1097/QAI.0000000000003680","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Online pharmacy HIV pre- and post-exposure prophylaxis (PrEP/PEP) provision is a novel strategy to expand HIV prevention coverage. In the ePrEP pilot study, we found online pharmacy PrEP/PEP was feasible and reached populations at HIV risk in Kenya. However, program costs data are lacking.</p><p><strong>Methods: </strong>We conducted a costing within the ePrEP pilot study in Nairobi from 11/01/2022-12/29/2023. We obtained costs from expense reports and conducted time-and-motion observations and staff interviews. We estimated total and unit costs in the first year of implementation, cost per client and per PrEP client-month (2023 US Dollars (USD)).</p><p><strong>Results: </strong>Overall, 229 clients initiated PrEP (507 months of PrEP coverage) and 1320 initiated PEP. Based on observed program volume, annual financial cost was $109,945 USD (PrEP: $19,456; PEP: $90,489). Cost per client was higher for PrEP than PEP ($85 vs $68.6), and cost per PrEP client-month was $38 (mean duration: 2.2 months). Main drivers of financial costs were courier-delivery of HIV testing kits and drugs (PrEP: 50.6%; PEP: 40.5%), demand generation (PrEP: 25.9%; PEP: 32.1%), and equipment, system development, and utilities (PrEP: 9.3%; PEP: 9.8%). Assuming a scaled-up client volume of 2500 (PrEP: 370; PEP: 2130) reduced per-client financial costs for PrEP ($65.5) and PEP ($56) and cost per PrEP client-month ($29.6).</p><p><strong>Conclusions: </strong>Costs of online PrEP/PEP provision is likely higher than clinic-based PrEP. Implementing cost sharing models including charging clients for HIV testing and optimizing courier delivery routes can increase program efficiencies. Our cost estimates can inform economic evaluations of online PrEP/PEP delivery.</p>","PeriodicalId":14588,"journal":{"name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAIDS Journal of Acquired Immune Deficiency Syndromes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/QAI.0000000000003680","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Online pharmacy HIV pre- and post-exposure prophylaxis (PrEP/PEP) provision is a novel strategy to expand HIV prevention coverage. In the ePrEP pilot study, we found online pharmacy PrEP/PEP was feasible and reached populations at HIV risk in Kenya. However, program costs data are lacking.

Methods: We conducted a costing within the ePrEP pilot study in Nairobi from 11/01/2022-12/29/2023. We obtained costs from expense reports and conducted time-and-motion observations and staff interviews. We estimated total and unit costs in the first year of implementation, cost per client and per PrEP client-month (2023 US Dollars (USD)).

Results: Overall, 229 clients initiated PrEP (507 months of PrEP coverage) and 1320 initiated PEP. Based on observed program volume, annual financial cost was $109,945 USD (PrEP: $19,456; PEP: $90,489). Cost per client was higher for PrEP than PEP ($85 vs $68.6), and cost per PrEP client-month was $38 (mean duration: 2.2 months). Main drivers of financial costs were courier-delivery of HIV testing kits and drugs (PrEP: 50.6%; PEP: 40.5%), demand generation (PrEP: 25.9%; PEP: 32.1%), and equipment, system development, and utilities (PrEP: 9.3%; PEP: 9.8%). Assuming a scaled-up client volume of 2500 (PrEP: 370; PEP: 2130) reduced per-client financial costs for PrEP ($65.5) and PEP ($56) and cost per PrEP client-month ($29.6).

Conclusions: Costs of online PrEP/PEP provision is likely higher than clinic-based PrEP. Implementing cost sharing models including charging clients for HIV testing and optimizing courier delivery routes can increase program efficiencies. Our cost estimates can inform economic evaluations of online PrEP/PEP delivery.

肯尼亚通过在线药房提供接触前和接触后预防服务的增量成本。
背景:在线药店提供艾滋病毒暴露前和暴露后预防(PrEP/PEP)是扩大艾滋病毒预防覆盖面的一种新策略。在ePrEP试点研究中,我们发现在线药房PrEP/PEP是可行的,并覆盖了肯尼亚艾滋病毒风险人群。然而,缺乏项目成本数据。方法:我们从2022年1月11日至2023年12月29日在内罗毕的ePrEP试点研究中进行了成本核算。我们从费用报告中获得成本,并进行时间和动作观察和工作人员访谈。我们估算了实施第一年的总成本和单位成本、每个客户和每个PrEP客户月的成本(2023美元)。结果:总体而言,229名患者开始了PrEP (PrEP覆盖507个月),1320名患者开始了PEP。根据观察到的项目数量,年度财务成本为109,945美元(PrEP: 19,456美元;PEP: 90489美元)。每位客户的PrEP成本高于PEP(85美元vs 68.6美元),每位PrEP客户月的成本为38美元(平均持续时间:2.2个月)。财务成本的主要驱动因素是艾滋病毒检测试剂盒和药物的快递(PrEP: 50.6%;PEP: 40.5%),需求生成(PrEP: 25.9%;PEP: 32.1%),以及设备、系统开发和公用事业(PrEP: 9.3%;PEP: 9.8%)。假设扩展后的客户端数量为2500 (PrEP: 370;PEP: 2130)降低了每位客户的财务成本(65.5美元)和PEP(56美元),以及每位PrEP客户每月的成本(29.6美元)。结论:在线PrEP/PEP提供的成本可能高于临床PrEP。实施成本分担模式,包括向客户收取艾滋病毒检测费用和优化快递路线,可以提高项目效率。我们的成本估算可以为在线PrEP/PEP交付的经济评估提供信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.80
自引率
5.60%
发文量
490
审稿时长
3-6 weeks
期刊介绍: JAIDS: Journal of Acquired Immune Deficiency Syndromes​ seeks to end the HIV epidemic by presenting important new science across all disciplines that advance our understanding of the biology, treatment and prevention of HIV infection worldwide. JAIDS: Journal of Acquired Immune Deficiency Syndromes is the trusted, interdisciplinary resource for HIV- and AIDS-related information with a strong focus on basic and translational science, clinical science, and epidemiology and prevention. Co-edited by the foremost leaders in clinical virology, molecular biology, and epidemiology, JAIDS publishes vital information on the advances in diagnosis and treatment of HIV infections, as well as the latest research in the development of therapeutics and vaccine approaches. This ground-breaking journal brings together rigorously peer-reviewed articles, reviews of current research, results of clinical trials, and epidemiologic reports from around the world.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信